GSK Ends PPAR-Gamma Diabetes Development, Studying New Indications
Executive Summary
GlaxoSmithKline will explore new indications for the PPAR-gamma agent GI-262,570 after terminating development of the compound for type 2 diabetes, the company told a third-quarter earnings call Oct. 23.
You may also be interested in...
GSK Florida Medicaid Deal Close; Discounts Are Not "Difficult," Garnier Says
GlaxoSmithKline's discounts to the Florida state Medicaid program are not out of line with agreements with other states, CEO J.P. Garnier told the Bear Stearns "virtual" healthcare conference Sept. 24.
GSK Has Generalized Anxiety For Paxil, Augmented Patent For Augmentin
GlaxoSmithKline is initiating direct-to-consumer advertising to support Paxil for generalized anxiety disorder to coincide with the market entrance of the first generic versions of Prozac.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011